Revelation Biosciences, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
REVB Nasdaq 3840 www.revbiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Revelation Biosciences, Inc.

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 12th, 2026 3:00 pm
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - Jan 7th, 2026 7:00 am
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting - Dec 1st, 2025 7:00 am
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year - Nov 20th, 2025 7:00 am
REVB Ready to Advance Groundbreaking Treatment - Nov 7th, 2025 4:07 am
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025 - Nov 6th, 2025 2:15 pm
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date - Oct 29th, 2025 7:00 am
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 - Oct 15th, 2025 3:00 pm
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds - Sep 11th, 2025 6:30 am
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data - Sep 10th, 2025 5:20 am
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data - Sep 9th, 2025 2:55 pm
Groundbreaking Results from REVB Point to Relief for Millions - Sep 9th, 2025 6:08 am
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study - Sep 9th, 2025 6:00 am
REVB To Release Test Results This Quarter - Aug 8th, 2025 6:04 am
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025 - Aug 8th, 2025 4:30 am
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research - Jul 24th, 2025 7:00 am
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study - Jul 16th, 2025 7:00 am
The early winner in the 'Dexit' war for corporate relocations: Nevada - Jul 10th, 2025 2:00 am
Investors Should Look at REVB as Top-Line Results Approach - Jul 9th, 2025 5:54 am
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - Jul 1st, 2025 3:26 pm